After years of negotiation and capacity-building, South Africa has been granted a licence to manufacture one of the world’s most important vaccines, Hexaxim. South Africa’s Biovac Institute (Biovac) will begin production of the vaccine next year, and follow in 2020 with anti-pneumonia inoculation Prevnar, marking the first local manufacture since the mid-1990s: decreased cost, increased availability and a spurring of economic growth are all set to follow.
BIOVAC – Local Vaccine Manufacture Returns to South Africa
